Partner David Rosen, who chairs the firm’s FDA regulatory practice, was quoted in a Law360 article, “FDA Focus: What Foley & Lardner’s Practice Chair is Watching,” about litigation and regulation he’s watching, the skills he looks for when hiring an FDA lawyer and the one FDA policy he’d change if he had a magic wand.
Rosen said the firm does a lot of work with compliance and enforcement, especially with data integrity issues. He also said he’s always been a “stickler” about making sure products meet appropriate standards of identity, strength, quality and purity at the time of use.
People
Related News
July 21, 2025
In the News
Nicholas O'Keefe Assesses 'Golden Share' in US Steel Deal
Foley & Lardner LLP partner Nicholas O'Keefe commented on the 'golden share' arrangement included as part of the approval of Nippon Steel's acquisition of U.S. Steel in Agenda, a Financial Times publication.
July 18, 2025
In the News
Matt Caplan Featured for Arrival to Foley – 'It's an exciting time'
Foley & Lardner LLP partner Matt Caplan is highlighted across press for his recent arrival to the firm's San Francisco office.
July 18, 2025
In the News
David Rosen on FDA's CRL Release – 'It hasn't happened in the past'
Foley & Lardner LLP partner David Rosen commented on the U.S. Food and Drug Administration's decision to publish a package of complete response letters to pharmaceutical companies in the PharmaVoice article, "Why FDA’s CRL release could open the door to lawsuits against pharma."